drugset / Trial / NCT02998047
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
1. Establish the MTD of Lintuzumab-Ac225 as monotherapy 2. Establish overall response rate (ORR) where ORR = CR + sCR+ VGPR+PR) 3. Confirm the safety profile of the treatment regimen 4. Estimate progression-free survival (PFS) and overall survival
Timeline
- Start
- 2016-12
- Primary completion
- 2020-05
- Completion
- 2020-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LINTUZUMAB ACTINIUM AC-225 | Other / unclassified | 0.25 unknown | Intravenous |
| Subject | LINTUZUMAB ACTINIUM AC-225 | Other / unclassified | 0.5 unknown | Intravenous |
| Subject | LINTUZUMAB ACTINIUM AC-225 | Other / unclassified | 1 unknown | Intravenous |
| Subject | LINTUZUMAB ACTINIUM AC-225 | Other / unclassified | 1.5 unknown | Intravenous |